ProCE Banner Activity

CE / CME

Webcast: Novel Targeted Approaches to the Contemporary Management of Migraine

In this dynamic video, expert faculty discuss the prevention and acute treatment of migraine.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: March 25, 2020

Expiration: March 24, 2021

No longer available for credit.

Share

Faculty

Jessica Ailani

Jessica Ailani, MD

Director
MedStar Georgetown Headache Center
Professor of Clinical Neurology
Department of Neurology
MedStar Georgetown University Hospital
Washington, DC

Robert G. Kaniecki

Robert G. Kaniecki, MD

Director, UPMC Headache Center
Chief, Headache Division
Director, Headache Fellowship Training Program
Assistant Director, Neurology Residency Training Program
Associate Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Allergan

Amgen, Inc.

Lundbeck

Target Audience

This program is intended for neurologists, neurology residents, headache and pain specialists, primary care physicians, nurse practitioners, physician assistants, and other healthcare providers who treat patients with migraine.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider frequent/chronic migraine as a clinical syndrome with a range of symptomatic, quality of life, and comorbid features
  • Identify common challenges with available pharmacotherapies that impede effective management of episodic and chronic migraine
  • Describe the role of CGRP in the immunopathogenesis of migraine and the evidence for effective reduction of migraine occurrence and improved measures of quality of life with CGRP receptor blockers
  • Describe the potential place in therapy of quarterly infusion and gepant CGRP blockers for migraine management
  • Differentiate the mechanism of action of the selective serotonin 5-HT1F agonist “ditan” class and respective safety profile from that of the triptan abortive therapies
  • Apply current guidelines and updated data in the optimal management of episodic and chronic migraine

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Jessica Ailani, MD

Director
MedStar Georgetown Headache Center
Professor of Clinical Neurology
Department of Neurology
MedStar Georgetown University Hospital
Washington, DC

Jessica Ailani, MD, FAHS, FAAN, has disclosed that she has received consulting fees from Allergan, Amgen, Biohaven, Health Monitor, Impel, Lilly, Lundbeck, Neurodiem, Revance, Satsuma, Teva, Theranica, and Zosano; funds for research support paid to her institution from Allergan, American Migraine Foundation, Biohaven, Lilly, and Zosano; and fees for non-CME/CE services from Allergan, Amgen, Biohaven, Lilly, Lundbeck, and Teva.

Robert G. Kaniecki, MD

Director, UPMC Headache Center
Chief, Headache Division
Director, Headache Fellowship Training Program
Assistant Director, Neurology Residency Training Program
Associate Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert Kaniecki, MD, has no relevant financial relationships to disclose.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

David C. Howard,

Editorial Contributor

David Howard, PharmD, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, NP, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 25, 2020, through March 24, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to apply current and emerging targeted treatment strategies in the management of patients with episodic and chronic migraine.